AstraZeneca cans cancer pipeline efforts

AstraZeneca facility at The Cove

In its fourth-quarter earnings out early Friday morning, U.K.-based Big Pharma AstraZeneca has cut two early-stage experimental meds.

The two axed drugs (PDF) are both aimed at cancer targets: The first is MEDI7247, an anti-ASCT2 antibody-drug conjugate, and an oleclumab plus AZD4635 CD73 and A2A inhibitor combo.

MEDI7247 was being directed against both solid and blood cancers and works by binding to ASCT2, which ultimately causes cell death. The drug had been in phase 1 tests in patients with selected relapsed/refractory hematological malignancies including acute myeloid leukemia, multiple myeloma and diffuse large B-cell lymphoma.

Virtual Event

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

Also in phase 1 was oleclumab in combo with AZD4635 targeting non-small cell lung cancer patients with an EGFR mutation.

Although much of its pipeline promise exists in drugs already approved, there were some experimental highlights moving into midstage testing, including two for cancer: selective estrogen receptor degrader AZD9833 for ER-positive breast cancer and PD-1/CTLA-4 bispecific mAb MEDI5752 for solid tumors.

There’s also AstraZeneca's GLP-1/glucagon dual agonist cotadutide for nonalcoholic steatohepatitis and its IL-33 mAb MEDI3506 for diabetic kidney disease and atopic dermatitis, which have made it past the first clinical hurdles.

Suggested Articles

Xerox is partnering with the ventilator manufacturer Vortran to help mass produce its portable, disposable hardware for the COVID-19 pandemic.

AstraZeneca and GlaxoSmithKline are looking to assist the U.K. government by establishing a joint testing lab at the University of Cambridge.

The Big Pharma is applying its own discovery capabilities to the task and helping to evaluate candidates identified by academic partners.